Wall Street Journal -- Abbott Laboratories reported a 40% drop in third-quarter earnings, weighed down by costs associated with layoffs, a baby-formula recall and the withdrawal of a diet drug due to safety concerns.
Wall Street Journal -- Abbott Laboratories reported a 40% drop in third-quarter earnings, weighed down by costs associated with layoffs, a baby-formula recall and the withdrawal of a diet drug due to safety concerns.
